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Abstract
Background—Influenza vaccination is administered throughout the influenza disease season, 
even as late as March. Given such timing, what is the value of vaccinating the population earlier 
than currently being practiced?
Methods—We used real data on when individuals were vaccinated in Allegheny County, 
Pennsylvania, and the following 2 models to determine the value of vaccinating individuals earlier 
(by the end of September, October, and November): Framework for Reconstructing 
Epidemiological Dynamics (FRED), an agent-based model (ABM), and FluEcon, our influenza 
economic model that translates cases from the ABM to outcomes and costs [health care and lost 
productivity costs and quality-adjusted life-years (QALYs)]. We varied the reproductive number 
(R0) from 1.2 to 1.6.
Results—Applying the current timing of vaccinations averted 223,761 influenza cases, $16.3 
million in direct health care costs, $50.0 million in productivity losses, and 804 in QALYs, 
compared with no vaccination (February peak, R0 1.2). When the population does not have 
preexisting immunity and the influenza season peaks in February (R0 1.2–1.6), moving individuals 
who currently received the vaccine after September to the end of September could avert an 
additional 9634–17,794 influenza cases, $0.6–$1.4 million in direct costs, $2.1–$4.0 million in 
productivity losses, and 35–64 QALYs. Moving the vaccination of just children to September (R0 
1.2–1.6) averted 11,366–1660 influenza cases, $0.6–$0.03 million in direct costs, $2.3–$0.2 
million in productivity losses, and 42–8 QALYs. Moving the season peak to December increased 
these benefits, whereas increasing preexisting immunity reduced these benefits.
Conclusion—Even though many people are vaccinated well after September/October, they 
likely are still vaccinated early enough to provide substantial cost-savings.
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Influenza vaccinations are administered throughout the influenza disease season, even as 
late as March, the tail-end end of most seasons. This may leave individuals unprotected for a 
sizeable duration of the season, which can start as early as September. The longer the 
unprotected period, the greater the chance the individual may contract influenza, incurring 
potentially avoidable absenteeism, clinic visits, hospitalizations, and deaths, as our previous 
studies have shown for children and elderly,1,2 those who are at highest risk for poor 
influenza outcomes.3 Individuals who delay vaccination may not be the only ones affected. 
Delaying vaccination can also allow greater influenza transmission (by failing to achieve a 
higher level of herd protection earlier) leaving both those never get vaccinated throughout 
the season and even those who are vaccinated earlier at higher risk.
Although numerous efforts have been made to increase influenza vaccination coverage by 
convincing more people to get vaccinated, there has been comparatively less emphasis on 
convincing those already compliant to get immunized earlier in the season. For example, 
workplace-based and school-based vaccination programs and initiatives such as National 
Influenza Vaccination Week, which is in December.4 Late vaccinees are apparently willing 
to get vaccinated but may be facing obstacles to getting vaccinated earlier in the season such 
as busy schedules, poor access to vaccination locations, or simple oversight. Therefore, 
could more benefits be garnered by focusing on administering vaccines to receptive persons 
rather than trying to convince those who oppose vaccination to accept it?
The question remains: what is the value of vaccinating the population earlier than they are 
currently getting vaccinated? Historically, between 1982 and 2013, influenza activity most 
often peaked in February (14 seasons, or 44% of the time), followed by December (6 
seasons, or 19% of the time), and January and March (5 seasons each, or 16% of the time).5 
We used data on when individuals were vaccinated in Allegheny County, Pennsylvania, and 
2 existing models to determine the value of getting these individuals to be vaccinated earlier: 
Framework for Reconstructing Epidemiological Dynamics (FRED), an agent-based model 
(ABM) of Allegheny County, a detailed computational simulation of the people, locations, 
and activities of the entire county,6,7 and FluEcon, our influenza economic model that can 
translate cases to influenza outcomes and costs.
METHODS
FRED ABM of Allegheny County
We used our previously described FRED ABM of Allegheny County, Pennsylvania,6–10 
which comprises a total population of 1,164,880. A collaboration of investigators (P.C., 
S.T.B., W.D.W., and B.Y.L., currently at RTI, the Pittsburgh Supercomputing Center, and 
Johns Hopkins, respectively) developed the initial ABM in 2008, which was used during the 
2009 H1N1 pandemic to help inform policy making at county through national levels. After 
which, this initial ABM was transcoded and served as the basis for the subsequently 
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developed FRED system by investigators at the University of Pittsburgh, Carnegie Mellon 
University, and Pittsburgh Supercomputing Center.10 The ABM represents each individual 
in Allegheny County with a computational agent. Just like a person, each agent has a set of 
characteristics (eg, age, sex, and employment status) and is assigned to a particular 
household, school (if the agent is of school age), and workplace (if the agent is employed). 
During the simulation, the model proceeds in discrete 1-day time steps. Each simulated day, 
the agents move among virtual representations of the county's households, schools, 
workplaces, and communities, where agents interact with each other. Agents' ages and 
locations are based on 2010 US census data.
At any given time, an agent is in one of 4 mutually exclusive influenza states: susceptible 
(S), exposed (E), infectious (I), or recovered (R). An agent in the S state has a probability of 
contracting influenza when contacting an agent in the I state. The transmission probability 
depends on the agents' ages and location and the reproductive rate (R0) of the epidemic 
(Appendix Table A1).11–13 If the agent in the S state contracts influenza, he/she moves into 
the E state and remains for the duration of the latent period (distribution with a mean of 1.2 
d). Once the latent period elapses, the agent transitions to the I state, in which he/she can 
transmit influenza to others and remain for the duration of the infectious period (distribution 
with a mean of 4.1 d). Once the infectious period elapses, the agent moves into the R state in 
which he/she is not infectious and immune to infection, and where they remained for the rest 
of the simulation. Vaccinating an agent in the S state had a probability (ie, the vaccine 
efficacy) of moving the agent to the R state 2 weeks after the vaccination occurred (to 
represent the time lag in the onset of immunity postvaccination). In addition, some agents 
could have preexisting immunity; these individuals started the simulation in the R state.
For this study, the primary output from the ABM was the number of influenza cases in each 
age group on each simulated day.
FluEcon: Influenza Economic Model
We developed FluEcon, our economic model, in Microsoft Excel (Microsoft, Redmond, 
WA) and utilized a Crystal Ball add-in (Oracle, Redwood City, CA), following our previous 
models,14–19 to translate influenza cases from the ABM into health outcomes and 
corresponding costs from the third party payer and societal perspectives. Appendix Table A2 
shows the model inputs. Each influenza case from the ABM had a probability of being 
symptomatic. Each symptomatic case then had probabilities of seeking ambulatory care, 
being hospitalized, or dying from influenza, each associated with a corresponding cost. 
Thus, the outcome of each case determined the costs accrued. All costs and probabilities 
were age specific when available.
Third party payer costs included all direct costs of illness (eg, ambulatory care visit, 
hospitalization) derived from nationally representative data sources. Societal costs included 
direct and indirect (ie, productivity losses due to absenteeism from work or school and 
mortality) costs. The median hourly wage for all occupations estimated productivity losses 
and assumed an 8-hour work day. A death resulted in accruing the net present value of that 
person's remaining lifetime earnings, based on their life expectancy.20,21 A 3% discount rate 
converted all costs into 2013 $US.
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Health effects were measured in quality-adjusted life-years (QALYs). Each influenza case 
accrued QALY values based on their age-dependent healthy QALY value attenuated by 
influenza's utility weight (either hospitalized or not) for the duration of their symptoms (if 
not hospitalized) or hospitalization (if hospitalized). For example, a child has a healthy 
QALY over the course of a year of 1, if he/she contracts influenza and are not hospitalized, 
we use the published utility weight for influenza without hospitalization (0.659) to attenuate 
the healthy value, resulting in 0.659 QALYs (1×0.659) for the 7-day symptom duration. By 
contrast, an adult has a healthy QALY value of 0.92 over a year, if he/she contracts 
influenza and is hospitalized, they accrue 0.473 QALYs (0.92×0.514, the published utility 
weight for influenza with hospitalization) for the hospitalization duration. We also 
considered QALYs from vaccination side effects.
Experiments
Current Coverage and Timing—The baseline scenario had individuals vaccinated based 
on the days indicated by the Influenza Vaccine Effectiveness Network Data (Fig. 1) where, 
66.2% of children 0–4 years old, 54.2% of children 5–9 years old, 33.7% of children 10–17 
years old, 28.6% of adults 18–44 years old, 42.7% of adults 45–64 years old, and 64.9% of 
elderly 65 years and older were vaccinated.
Vaccinating Population Earlier—Using the same model we moved vaccinated 
individuals earlier; scenarios explored earlier vaccination, ensuring that vaccination was 
completed by the end of: (1) November, (2) October, and (3) September. In other words, 
anyone who typically was vaccinated after the selected month received the vaccine by the 
end of the specified month (eg, a person who normally received the vaccine in February was 
simulated to be vaccinated in November). Everyone who received the vaccine before the 
specified month was vaccinated at the same time as they were in the baseline simulation 
(Fig. 1). Additional scenarios vaccinated only children earlier, as children may be more 
readily vaccinated earlier (eg, enabled by target programs), are a high-risk group, and are 
thought to be high transmitters.
Sensitivity analyses varied R0 (1.2–1.6), the epidemic peak (December to February), and the 
percentage of the population with preexisting immunity (0%, 20%, and 40%), that is, those 
starting the simulation in the R state rather than the S state. Another scenario evaluated 
increases in vaccination coverage (5% and 10% increase in each age group) while 
maintaining the current timing.
RESULTS
Table 1 shows the epidemiologic and economic results for different vaccination scenarios 
for an influenza season peak of February. Figure 2 shows the corresponding epidemic curves 
for season peaks of December and February when there is no preexisting immunity. As 
influenza seasons differ year to year, our results summarize the variability in the range of 
costs and QALYs across varying transmission dynamics and season characteristics.
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When there is no vaccination, varying R0 from 1.2 and 1.6 results in approximately 229,000 
more cases generating an additional $21.0 million in direct costs, $52.0 million in 
productivity losses, and 807 additional QALYs (Table 1). As the amount of preexisting 
immunity in the population increases, the difference in the number of influenza cases and 
their related costs and health effects between R0 1.2 and 1.6 decrease (Table 1). This 
highlights the variability from season to season (as there is no one most common influenza 
season) and how these parameters relate to epidemiologic and economic outcomes.
Current Vaccination Schedule
Tables 1 and 2, and Figure 2 show how the current timing of vaccination reduces the 
epidemic curve and impacts economic outcomes. The impact of vaccination depends on the 
transmission dynamics of the influenza season, on R0, amount of preexisting immunity, and 
season peak. Vaccination can lead to a 1.9- to 14-fold decrease in attack rate, depending on 
these transmission dynamics. The current vaccination timing averted fewer cases when the 
season peaked in December (29,187–252,106 cases averted), increasing with R0 values and 
decreasing with higher levels of preexisting immunity.
The mean total vaccination cost was $3,451,555 (SD = $325,879) for Centers for Disease 
Control and Prevention vaccine prices and $4,810,976 (SD = $473,959) for private sector 
vaccine prices. When combined with the direct costs, third party payer costs can be 
determined for vaccine price points. Societal costs for both vaccine price points can be 
calculated as the respective vaccination costs plus direct costs plus productivity losses. For 
example, given the current timing, with private sector vaccine costs, the third party payer 
costs were $16.0 million and societal costs were $52.3 million (December peak, R0 1.2).
Vaccinating All Age Groups Earlier Than the Current Schedule
When the influenza season peaks in February, shifting vaccination for all ages earlier can 
reduce the attack rate from 13.7% (current schedule) to 12.8% regardless of when 
vaccination was complete (ie, attack rate same for shifts to September, October, or 
November) with R0 1.2 and no preexisting immunity. Earlier vaccination could avert ~34 
QALYs, $0.6 million in direct costs, and $2.1 million in productivity losses (Table 1).
Table 1 can be used to determine the costs and QALYs averted by shifting the timing of 
vaccination from the current schedule and to determine the cost per person countywide 
(divide by 1,164,880). For example, completing vaccination by the end of October can avert 
10,093 cases, $0.7 million in direct costs (saving $0.6 per person countywide), $2.2 million 
in productivity losses (saving $2 per person countywide), and 37 QALYs (R0 1.2; no 
preexisting immunity). These saving thresholds represent the investment ceilings that can be 
made to promote earlier vaccination (ie, shift vaccination) and remain cost-neutral.
When the influenza season peaks earlier (eg, December), it is more important to vaccinate 
earlier. Shifting the timing of vaccination had a greater impact with a December peak. A 
September shift provided the greatest gains, decreasing the attack rate from 15.6% to 12.8%, 
averting an additional 33,139 cases, $2.2 million in direct costs, $7.2 million in productivity 
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losses, and 120 QALYs (R0 1.2, no preexisting immunity). This decreased with the amount 
of preexisting immunity in the population so that at 40%, shifting vaccination timing had 
little impact. A September shift yielded the greatest change, averting 73 cases, $5295 in 
direct costs, and $17,167 in productivity losses (December peak, R0 1.2). At an R0 of 1.6, 
shifting vaccination could avert ≤11,687 cases and save ≤$680,627 in direct costs, and ≤
$2,415,913 in productivity losses.
Figure 2 shows how earlier vaccination impacts the epidemic curves for both peaks and R0 
values with no preexisting immunity. Earlier vaccination shifts the curve later in the 
influenza season and reduces the peak; this is most prominent with a December peak and R0 
1.2, whereas earlier vaccination has little impact with a February peak and R0 1.6 as the 
curves are stacked on top of each other. Table 2 provides the age breakdown for these 
epidemic curves for R0 1.2 and no preexisting immunity, showing the month for completing 
vaccination had little impact with a late peak (February).
Figure 3 shows the cost-savings per vaccinated person shifted earlier for both peaks and R0 
values. These savings represent the amount that could be invested per person to promote 
earlier vaccination and remain cost-neutral. Vaccinating everyone by the end of September 
(51,461 earlier vaccinations) saved $12–$72 and $41–$208 per shifted person in direct costs 
and productivity losses, respectively.
Vaccinating Only Children Earlier Than the Current Schedule
When only vaccinating children by the end of September (everyone else remains at current 
schedule), there were 147,670 total cases (11,366 fewer cases than the current schedule), 
saving $0.6 million in direct costs, $2.3 million in productivity losses, and 42 QALYs 
(February peak, R0 1.2, no preexisting immunity). Compared with the other vaccination 
shifts, it would be better to vaccinate only children by the end of September with a February 
peak, but vaccinating everyone by the end of September or October would be better than 
only vaccinating children by the end of September with a December peak (R0 1.2). 
However, at R0 1.6, vaccinating everyone earlier, regardless of when, resulted in fewer cases 
and incurred lower costs than only vaccinating children earlier (December and February 
peaks).
Increasing Vaccination Coverage
Table 2 shows the epidemiologic and economic impact of increasing vaccination coverage 
compared with the current timing and earlier vaccination. Increasing coverage could result 
in attack rates of 12.8%–27.2% (5% coverage increase) and 11.6%–26.1% (10% coverage 
increase) for R0 1.2–1.6 (February peak). With a February peak (R0 1.2), a 5% increase in 
coverage among all age groups would be comparable with earlier vaccination (similar attack 
rates and number of cases), however, a 10% vaccination coverage increase would be better 
than any of the shifts (Table 2). Results were similar for R0 1.6. With a December peak, 
vaccinating everyone earlier would be better than a 5% or 10% increase in coverage (R0 1.2 
and R0 1.6). Vaccinating children by the end of September would be better than increasing 
vaccination coverage by 5% at an R0 of 1.2 (regardless of the season peak) and R0 of 1.6 
Lee et al. Page 6













with a December peak. However, vaccinating children by the end of September would only 
be better than a 10% increase in coverage at R0 1.2 (regardless of peak).
DISCUSSION
Our study quantifies the potential benefits and cost-savings of administering influenza 
vaccination to the population earlier than current practice. In a majority of influenza seasons, 
which peak in February or later (59% over past 32 y5), the current timing of vaccination 
appears to be early enough. However, earlier vaccination could provide additional cost-
savings in influenza seasons that peak in December or earlier (25% over past 32 y5). These 
cost-savings would be greater than the cost-savings garnered from increasing vaccination 
coverage by 5%–10% for seasons that peak in or before December (ie, earlier vaccination 
would be better than increasing vaccination coverage), whereas increasing coverage may be 
better seasons with a later peak (in or after February, regardless of R0). From season to 
season the comparison of increasing coverage versus earlier vaccination may have a 
different answer. In the long run, however, with 59% of influenza seasons peaking in 
February or later, increasing coverage by >5% may yield more returns than vaccinating 
earlier.
As influenza seasons differ from year to year, shifting vaccination earlier may have value in 
some seasons but not all of them and potentially not in over half. For any given season, the 
expected savings if completing vaccination by the end of September would range between 
$21,000–$1,300,000 in direct costs, $78,000–$3,800,000 in productivity losses, and 2–60 
QALYs. This corresponds to up to 1.88 extra healthy days per influenza case averted or over 
1 day saved/gained, 1 day of productivity, time with family or friends, etc. If vaccination 
were completed by the end of November, expected savings ranged from $6000–$1,100,000 
in direct costs, $24,000–$3,100,000 in productivity losses, and 1–48 QALYs. Both 
increasing coverage and earlier vaccination would be helpful, but if having to choose, 
increasing coverage has value across all seasons, whereas earlier vaccination has value only 
were the peak is earlier than February (40% of seasons). For any given season, for coverage 
increases of 5%–10%, the maximum expected savings ranged from $743,000–$1,400,000 in 
direct costs, $1,300,000–$3,200,000 in productivity losses, and 27–56 QALYs.
Our results may provide benchmarks to help determine how much should be invested in 
getting people vaccinated earlier. Barriers to early vaccination include variability in timing 
of influenza vaccine production, variability in timing of influenza vaccine distribution, 
historical emphasis on distribution of vaccine in October and November, August as a 
vacation month and start of schools year, typically in late August. Historically, influenza 
vaccine production was limited by the small number of manufacturers in the US market, and 
time needed for egg-based production and to optimize growth for new strains. However, the 
market has changed with the entrance of more manufacturers, larger facilities, and cell-
based and recombinant vaccines that do not require eggs. With conventional egg-based 
production measures it is not clear how early vaccines could be available, but newer 
technologies (cell-based and recombinant vaccines) could make vaccines available much 
earlier (eg, August).
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There are several ways to increase the feasibility of earlier vaccination. First, earlier 
vaccination in medical settings can be achieved by a combination of automatic patient 
notification via e-mail, autodialing, text messaging, and express vaccination services that 
operate under standing orders. Second, employers and community vaccinators (eg, local 
pharmacies) can offer vaccination earlier. Third, vaccination could be offered in school 
settings early, given that many school systems start in late August. There is a tremendous 
amount of variability in the costs of programs to shift vaccination earlier. Rather than 
represent a single program (which may be difficult to cost out or vary by location), our 
results show the ceiling amount that can be invested in these programs and remain cost-
neutral. In addition, each of these initiatives incur may have variable success in encouraging 
earlier vaccination. Thus, the costs of these activities must be weighed against the benefits. 
Systematic reviews and meta-analyses already describe ways to increase vaccination rates22; 
again, costs are variable and must be weighed against the benefits.
Moreover, we did not account for the possibility that influenza vaccine immunoprotection 
could wane over the season's course, providing disincentive to vaccination that is too early 
in the season. Data on such waning immunity is still equivocal. In a review, 8 of 8 studies 
found seroprotection lasting ≥4 months for H3N2 and 5 of 7 for H1N1 or B.23 In another 
study, seroprotection rates declined significantly but still met regulatory criteria (6 mo 
postvaccination).24 The live attenuated influenza vaccine has been shown to have protection 
that lasts over a year.25 The US influenza vaccine effectiveness network has found residual 
protection from the prior vaccine season.26
Our study endeavored to remain conservative. Vaccine efficacy varies from year to year 
depending on strain matching and vaccine presentation, we modeled vaccine efficacy as a 
range to account for these potential differences. However, actual efficacy may be higher or 
lower than that modeled. We did not include additional productivity losses beyond 
hospitalization, although a person may experience symptoms after hospitalization. Our 
model did not include other comorbid conditions, which may exacerbate influenza or require 
additional medical care and accrue additional costs. By definition, all models are 
simplification of real life, and as such cannot represent every possibility or outcome.27 The 
course of an actual epidemic may not conform to our model's data and assumptions. Our 
study draws data from sources of varying rigor and quality.
CONCLUSIONS
Even though many people are getting vaccinated well after the September through October 
timeframe, these vaccinations likely are still occurring early enough to provide substantial 
cost-savings. Our study quantifies the potential benefits and cost-savings of vaccinating 
against influenza earlier than current practice. Depending on the timing of the influenza 
season peak, influenza transmissibility, and preexisting immunity, vaccinating those who 
typically receive the vaccine later by the end of September could avert up to $3.7 million in 
direct costs, $10.7 million in productivity losses, and 168 QALYs. While moving 
vaccinations earlier from current practice yielded some benefits and cost-savings, investing 
in increasing coverage may yield greater benefits for later season peaks.
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APPENDIX
TABLE A1
Agent-based Model Transmission and Contact Parameters
Contact Group Infectious Individual Susceptible Individual Transmission Probability
Household Adult Adult 0.4
Household Adult Child 0.3
Household Child Adult 0.3
Household Child Child 0.6
Elementary school Student Student 0.0435
Middle school Student Student 0.0375
High school Student Student 0.0315
Workplace Adult Adult 0.0575
Hospital Health care worker Health care worker 0.0575
Hospital Health care worker Patient 0.01
Hospital Patient Health care worker 0.01
Community All Adult 0.00480
Community All Child 0.00255
Social network Location Individual Mean contacts per day
School Classroom Student 13.5
School Outside classroom Student 15
Community (weekday) Outside of school Student 16.2
Community (weekend) Outside of school Student 24.3
Community Community All 32.4
Workplace Within office Worker 2
Workplace Outside of office Worker 8
Health care facility Within ward or clinic Health care worker 2
Health care facility Outside ward or clinic Health care worker 8
Health care facility With patients Health care worker 30
TABLE A2
Select ABM Parameters and Economic Model Input Parameters
Parameters Mean or Median SE or Range Source
Other ABM parameters
 Proportion receiving TIV (of those vaccinated)*
  6 mo–4 y 93.06
  5–9 y 71.03
  10–17 y 80.11
Lee et al. Page 9













Parameters Mean or Median SE or Range Source
  18–44 y 97.91
  45–64 y 100
  65 y and older 100
 Proportion receiving LAIV (of those vaccinated)*
  6 mo–4 y 6.94
  5–9 y 28.97
  10–17 y 19.89
  18–44 y 2.09
 TIV vaccine efficacy
  6 mo–4 y 59.0 51.0–65.0
†
Expert Opinion28
  5–9 y 59.0 51.0–66.0
†
Expert Opinion28
  10–17 y 59.0 51.0–67.0
†
Expert Opinion28
  18–44 y 59.0 51.0–68.0
†
Expert Opinion28
  45–64 y 59.0 51.0–69.0
†
Expert Opinion28
  65 y and older 54.0 47.0–62.0
†
Expert Opinion28
 LAIV vaccine efficacy
  6 mo–17 y 83.0 69.0–91.0
†
Expert Opinion28




 Costs (2013 US$)
  Vaccination
   TIV (CDC cost per dose)
    6 mo–3 y 10.49 2.49 29
    4 y and older 10.00 1.89 29
    9 y and older 9.70 1.76 29
    18–64 y olds 8.85 1.99 29
    65 y and older 8.50 1.67 29
   LAIV (CDC cost per dose)
    2–49 y olds 17.3 29
   TIV (private sector cost per dose)
    6 mo–3 y 12.97 3.22 29
    4 y and older 12.96 1.82 29
    9 y and older 12.44 1.90 29
    18–64 y olds 13.04 2.78 29
    65 y and older 12.70 2.65 29
   LAIV (private sector cost per dose)
    2–49 y olds 21.7 29
  Hourly wage 17.21 8.96–42.99 20
   Outpatient visit given Influenza
    < 1 y old 78.46 30
    1–17 y old 83.91 30
    18–44 y old 105.59 30
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Parameters Mean or Median SE or Range Source
    45–64 y old 96.26 31
    65–84 y old 92.74 31
   Hospitalization given Influenza
    < 1 y old 5650.47 1124.88 32
    1–17 y old 6824.13 801.07 32
    18–44 y old 8880.10 1085.17 32
    45–64 y old 14,703.65 1699.23 32
    65–84 y old 9810.63 846.85 32
    85 y and older 8953.97 901.00 32
Probabilities
 Side effects from TIV 1.0 Pink Book
 Side effects from LAIV 7.0 Pink Book
 Symptomatic influenza 66.9 58.3–74.5 33
 Missing work 72.0 34
 Missing school 69.0 35
 Ambulatory care visit given influenza
  0–4 y old 45.5 9.8 36
  5–17 y old 31.8 6.1 36
  18–64 y old 31.3 1.4 36
  65 y and older 62.0 2.7 36
 Hospitalization given influenza
  0–4 y old 1.41 0.47 36
  5–17 y old 0.06 0.02 36
  18–49 y old 0.42 0.14 36
  50–64 y old 1.93 0.64 36
  65 y and older 4.21 1.4 36
 Morality given influenza
  0–4 y old 0.004 0.001 36
  5–17 y old 0.001 0 36
  18–49 y old 0.009 0.003 36
  50–64 y old 0.134 0.045 36
  65 y and older 1.17 0.39 36
Durations
 Ambulatory care visit (h) 4 Assumption
 Work missed (d) 1.5–4.9 37
 School missed (d) 2.54 35
 Duration of symptoms (d) 7 38
 Hospitalization (d)
  < 1 y old 3.3 0.4 32
  1–17 y old 3.4 0.2 32
  18–44 y old 4.2 0.3 32
  45–64 y old 5.7 0.4 32
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Parameters Mean or Median SE or Range Source
  65–84 y old 4.9 0.3 32
  85 y and older 5.5 0.7 32
Utility weights
 Healthy QALY
  < 17 y old 1 39
  18–64 y old 0.92 39
  65 y and older 0.84 39
 Influenza, no hospitalization utility weight 0.659 0.106 40–19
 Influenza, hospitalization, utility weight 0.514 0.089 42,49,50
 Side effects utility weight 0.940 0.041 18,40,42,43,47
ABM indicates agent-based model; CDC, Centers for Disease Control and Prevention; LAIV, live attenuated influenza 
vaccine; QALY, quality-adjusted life-years; TIV, trivalent inactivated influenza vaccine.
*
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Number of persons in each age group vaccinated each week in the agent-based model. A, 
Current vaccination coverage and timing, B, Vaccination completed by the end of 
September, C, Vaccination completed by the end of October, and D, Vaccination completed 
by the end of November. The current vaccination coverage and timing are from Allegheny 
County in 2011.
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Epidemiologic curves for an influenza season peaking in February and December with an R0 
of 1.2 and 1.6.
Lee et al. Page 16














Cost-savings per vaccinated person shifted earlier for December and February influenza 
season peaks with an R0 of 1.2 and 1.6. Direct costs and productivity losses per vaccinated 
person shifted if vaccinating by the end of September, October, and November.
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TABLE 1
Epidemiologic and Economic Outcomes for Various Vaccination Timing Strategies for an Influenza Season 
With a February Peak in Alleghany County, PA (Total Population 1,164,880)
Vaccination Timing
No Vaccination Current Schedule By End of September By End of October




  Attack rate (%) 32.9 13.7 12.8 12.8 12.8
  No. influenza cases 382,796 159,035 149,401 148,943 149,462
  Direct health care costs*
† 26.1 (5.2) 9.9 (2.0) 9.3 (1.8) 9.2 (1.8) 9.3 (1.8)
  Productivity losses*
† 84.4 (45.1) 34.3 (18.4) 32.2 (17.3) 32.1 (17.2) 32.2 (17.3)
  QALYs lost* 1383 (157) 579 (65) 544 (62) 543 (61) 545 (62)
 R0 1.6
  Attack rate (%) 52.6 28.4 26.9 26.9 26.9
  No. influenza cases 612,310 331,183 313,389 313,372 313,791
  Direct health care costs*
† 46.7 (9.9) 23.7 (5.0) 22.3 (4.7) 22.3 (4.7) 22.3 (4.7)
  Productivity losses*
† 140.9 (76.5) 72.5 (39.9) 68.5 (37.7) 68.5 (37.7) 68.6 (37.7)
  QALYs lost* 2193 (248) 1189 (128) 1125 (121) 1125 (121) 1127 (121)
20% preexisting immunity
 R0 1.2
  Attack rate (%) 16.8 2.2 1.8 1.8 1.8
  No. influenza cases 196,040 25,809 21,379 21,313 20,915
  Direct health care costs*
† 12.3 (2.4) 1.4 (0.3) 1.2 (0.2) 1.2 (0.2) 1.2 (0.2)
  Productivity losses*
† 42.0 (22.9) 5.4 (2.9) 4.5 (2.4) 4.4 (2.4) 4.4 (2.4)
  QALYs lost* 716 (77) 95 (10) 79 (8) 79 (8) 77 (8)
 R0 1.6
  Attack rate (%) 31.2 14.2 13.3 13.3 13.3
  No. influenza cases 363,181 164,869 154,792 155,249 154,961
  Direct health care costs*
† 25.7 (5.7) 10.7 (2.2) 10.0 (2.1) 10.0 (2.1) 10.0 (2.1)
  Productivity losses*
† 73.5 (44.7) 32.5 (19.5) 30.5 (18.2) 30.6 (18.3) 30.5 (18.3)
  QALYs lost* 1305 (145) 596 (66) 559 (62) 561 (62) 560 (62)
40% preexisting immunity
 R0 1.2
  Attack rate (%) 2.8 0.2 0.1 0.2 0.2
  No. influenza cases 32,172 2172 1314 2305 1885
  Direct health care costs*
† 1.8 (0.3) 0.12 (0.02) 0.07 (0.01) 0.12 (0.02) 0.11 (0.02)
  Productivity losses*
† 6.5 (3.4) 0.4 (0.2) 0.3 (0.1) 0.5 (0.2) 0.4 (0.2)
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Vaccination Timing
No Vaccination Current Schedule By End of September By End of October
By End of 
November
  QALYs lost* 118 (13) 8 (1) 5 (1) 9 (1) 7 (1)
 R0 1.6
  Attack rate (%) 13.3 1.8 1.4 1.5 1.6
  No. influenza cases 155,002 21,360 16,363 17,632 17,999
  Direct health care costs*
† 10.1 (2.0) 1.2 (0.2) 0.9 (0.2) 1.0 (0.2) 1.0 (0.2)
  Productivity losses*
† 33.4 (18.0) 4.5 (2.4) 2.4 (1.8) 3.7 (2.0) 3.8 (2.0)
  QALYs lost* 563 (62) 78 (9) 60 (7) 65 (7) 66 (7)
Does not include vaccinations costs.
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